Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (161-170 of 320) with videos related to

Pageof 32
Sort By:
Breast Care (Basel, Switzerland)|June 29, 2012
Treatment of Bone Metastases in Patients with Advanced Breast CancerMichael Gnant, Marija Balic, Edgar Petru, et al.
Anti-Cancer Drugs|June 1, 2000
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancerT Brodowicz, W J Koestler, S Tomek, et al.
Clinical Immunology and Immunopathology|August 1, 1994
Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivoG G Steger, W C Pierce, R Figlin, et al.
Annals of Hematology|February 1, 1992
Simultaneous occurrence of t(14;18) and t(8;22) common acute lymphoblastic leukemiaC Marosi, P Bettelheim, A Chott, et al.
The Oncologist|June 30, 2012
Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancerMatthias Preusser, Gerhard Fülöp, Anna Sophie Berghoff, et al.
Breast Cancer Research and Treatment|June 1, 1995
Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?G J Locker, I Simonitsch, R M Mader, et al.
Anti-Cancer Drugs|April 6, 2001
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patientsG J Locker, C Wenzel, M Schmidinger, et al.
International Journal of Cancer|September 8, 2004
Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profilingWolfgang M Schmidt, Maria Kalipciyan, Eva Dornstauder, et al.
The New England Journal of Medicine|July 23, 1992
Cutaneous reactions to GM-CSF in inflammatory breast cancerG G Steger, G Locker, H Rainer, et al.
Oncology|March 1, 1995
New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancerG J Locker, R M Mader, J Braun, et al.
Pageof 32

Showing results (161-170 of 320) with videos related to

Sort By:
Pageof 32
Breast Care (Basel, Switzerland)|June 29, 2012
Treatment of Bone Metastases in Patients with Advanced Breast CancerMichael Gnant, Marija Balic, Edgar Petru, et al.
Anti-Cancer Drugs|June 1, 2000
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancerT Brodowicz, W J Koestler, S Tomek, et al.
Clinical Immunology and Immunopathology|August 1, 1994
Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivoG G Steger, W C Pierce, R Figlin, et al.
Annals of Hematology|February 1, 1992
Simultaneous occurrence of t(14;18) and t(8;22) common acute lymphoblastic leukemiaC Marosi, P Bettelheim, A Chott, et al.
The Oncologist|June 30, 2012
Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancerMatthias Preusser, Gerhard Fülöp, Anna Sophie Berghoff, et al.
Breast Cancer Research and Treatment|June 1, 1995
Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?G J Locker, I Simonitsch, R M Mader, et al.
Anti-Cancer Drugs|April 6, 2001
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patientsG J Locker, C Wenzel, M Schmidinger, et al.
International Journal of Cancer|September 8, 2004
Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profilingWolfgang M Schmidt, Maria Kalipciyan, Eva Dornstauder, et al.
The New England Journal of Medicine|July 23, 1992
Cutaneous reactions to GM-CSF in inflammatory breast cancerG G Steger, G Locker, H Rainer, et al.
Oncology|March 1, 1995
New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancerG J Locker, R M Mader, J Braun, et al.
Pageof 32